Monotherapy of metastatic breast cancer: A review of newer agents

Charles Vogel, Jean Marc Nabholtz

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose. New agents for the palliative treatment of metastatic breast cancer have emerged in the 1990s. This review summarizes the response rates of these agents with an emphasis on recent findings, such as presentations from the 1998 Meeting of the American Society of Clinical Oncology. Methods. The English medical literature was reviewed to identify clinical trials involving monotherapy for the treatment of metastatic breast cancer. Three agents-paclitaxel, vinorelbine, and docetaxel-are emphasized because their databases are extensive enough to allow interesting comparisons. Liposomal- encapsulated anthracyclines, losoxantrone, gemcitabine, oral surrogates of continuous-infusion fluorouracil, raltitrexed, LY 231514, edatrexate, topoisomerase I inhibitors, and trastuzumab are reviewed briefly. Results. Many of the new agents produce response rates approaching or even surpassing those achievable with doxorubicin monotherapy. Compared with older agents, some new agents have improved or at least different safety profiles, and some are easier to administer. Discussion and conclusions. The new agents offer useful therapeutic options that make them suitable for combining with each other and with older agents, which could result in more effective regimens for metastatic disease, and, ultimately, primary disease in the adjuvant setting. The chemotherapeutic paradigms governing the management of breast cancer for the past three decades are likely to change as we move into the 21st century.

Original languageEnglish
Pages (from-to)17-33
Number of pages17
JournalOncologist
Volume4
Issue number1
StatePublished - Mar 8 1999

Fingerprint

losoxantrone
docetaxel
Breast Neoplasms
gemcitabine
Pemetrexed
Topoisomerase I Inhibitors
Anthracyclines
Paclitaxel
Palliative Care
Fluorouracil
Doxorubicin
Clinical Trials
Databases
Safety
Therapeutics
edatrexate
raltitrexed
vinorelbine
Trastuzumab

Keywords

  • Breast neoplasms
  • Docetaxel
  • Paclitaxel
  • Review
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Monotherapy of metastatic breast cancer : A review of newer agents. / Vogel, Charles; Nabholtz, Jean Marc.

In: Oncologist, Vol. 4, No. 1, 08.03.1999, p. 17-33.

Research output: Contribution to journalArticle

Vogel, Charles ; Nabholtz, Jean Marc. / Monotherapy of metastatic breast cancer : A review of newer agents. In: Oncologist. 1999 ; Vol. 4, No. 1. pp. 17-33.
@article{0150eb79bdbc4a3883db327c154a7417,
title = "Monotherapy of metastatic breast cancer: A review of newer agents",
abstract = "Purpose. New agents for the palliative treatment of metastatic breast cancer have emerged in the 1990s. This review summarizes the response rates of these agents with an emphasis on recent findings, such as presentations from the 1998 Meeting of the American Society of Clinical Oncology. Methods. The English medical literature was reviewed to identify clinical trials involving monotherapy for the treatment of metastatic breast cancer. Three agents-paclitaxel, vinorelbine, and docetaxel-are emphasized because their databases are extensive enough to allow interesting comparisons. Liposomal- encapsulated anthracyclines, losoxantrone, gemcitabine, oral surrogates of continuous-infusion fluorouracil, raltitrexed, LY 231514, edatrexate, topoisomerase I inhibitors, and trastuzumab are reviewed briefly. Results. Many of the new agents produce response rates approaching or even surpassing those achievable with doxorubicin monotherapy. Compared with older agents, some new agents have improved or at least different safety profiles, and some are easier to administer. Discussion and conclusions. The new agents offer useful therapeutic options that make them suitable for combining with each other and with older agents, which could result in more effective regimens for metastatic disease, and, ultimately, primary disease in the adjuvant setting. The chemotherapeutic paradigms governing the management of breast cancer for the past three decades are likely to change as we move into the 21st century.",
keywords = "Breast neoplasms, Docetaxel, Paclitaxel, Review, Vinorelbine",
author = "Charles Vogel and Nabholtz, {Jean Marc}",
year = "1999",
month = "3",
day = "8",
language = "English",
volume = "4",
pages = "17--33",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - Monotherapy of metastatic breast cancer

T2 - A review of newer agents

AU - Vogel, Charles

AU - Nabholtz, Jean Marc

PY - 1999/3/8

Y1 - 1999/3/8

N2 - Purpose. New agents for the palliative treatment of metastatic breast cancer have emerged in the 1990s. This review summarizes the response rates of these agents with an emphasis on recent findings, such as presentations from the 1998 Meeting of the American Society of Clinical Oncology. Methods. The English medical literature was reviewed to identify clinical trials involving monotherapy for the treatment of metastatic breast cancer. Three agents-paclitaxel, vinorelbine, and docetaxel-are emphasized because their databases are extensive enough to allow interesting comparisons. Liposomal- encapsulated anthracyclines, losoxantrone, gemcitabine, oral surrogates of continuous-infusion fluorouracil, raltitrexed, LY 231514, edatrexate, topoisomerase I inhibitors, and trastuzumab are reviewed briefly. Results. Many of the new agents produce response rates approaching or even surpassing those achievable with doxorubicin monotherapy. Compared with older agents, some new agents have improved or at least different safety profiles, and some are easier to administer. Discussion and conclusions. The new agents offer useful therapeutic options that make them suitable for combining with each other and with older agents, which could result in more effective regimens for metastatic disease, and, ultimately, primary disease in the adjuvant setting. The chemotherapeutic paradigms governing the management of breast cancer for the past three decades are likely to change as we move into the 21st century.

AB - Purpose. New agents for the palliative treatment of metastatic breast cancer have emerged in the 1990s. This review summarizes the response rates of these agents with an emphasis on recent findings, such as presentations from the 1998 Meeting of the American Society of Clinical Oncology. Methods. The English medical literature was reviewed to identify clinical trials involving monotherapy for the treatment of metastatic breast cancer. Three agents-paclitaxel, vinorelbine, and docetaxel-are emphasized because their databases are extensive enough to allow interesting comparisons. Liposomal- encapsulated anthracyclines, losoxantrone, gemcitabine, oral surrogates of continuous-infusion fluorouracil, raltitrexed, LY 231514, edatrexate, topoisomerase I inhibitors, and trastuzumab are reviewed briefly. Results. Many of the new agents produce response rates approaching or even surpassing those achievable with doxorubicin monotherapy. Compared with older agents, some new agents have improved or at least different safety profiles, and some are easier to administer. Discussion and conclusions. The new agents offer useful therapeutic options that make them suitable for combining with each other and with older agents, which could result in more effective regimens for metastatic disease, and, ultimately, primary disease in the adjuvant setting. The chemotherapeutic paradigms governing the management of breast cancer for the past three decades are likely to change as we move into the 21st century.

KW - Breast neoplasms

KW - Docetaxel

KW - Paclitaxel

KW - Review

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0033061808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033061808&partnerID=8YFLogxK

M3 - Article

C2 - 10337368

AN - SCOPUS:0033061808

VL - 4

SP - 17

EP - 33

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -